Abstract In recent years, nanodiamonds have emerged from primarily an industrial and mechanical applications base, to potentially underpinning sophisticated new technologies in biomedical and quantum science. Nanodiamonds are relatively inexpensive, biocompatible, easy to surface functionalise and optically stable. This combination of physical properties are ideally suited to biological applications, including intracellular labelling and tracking, extracellular drug delivery and adsorptive detection of bioactive molecules. Here we describe some of the methods and challenges for processing nanodiamond materials, detection schemes and some of the leading applications currently under investigation.
Introduction
Nanodiamonds are typically classed as diamond particles less than 100 nm in size and are of both natural and synthetic origins. They are used in many applications, including electrochemical coatings (Dolmatov 2006; Baidakova and Vul' 2007) , polymer compositions (Akopyan et al. 2004; Dolmatov 2006) , polishing (Artemov 2004; Dolmatov 2006) , and lubricants (Dolmatov 2006) . More recently, they have been the subject of intense research in quantum optics (Kurtsiefer et al. 2000) , nanoscale magnetometry (Balasubramanian et al. 2008; Maze et al. 2008) and biomedical applications that range from drug delivery to intracellular tracking Pramatarova et al. 2007; Chang et al. 2008b; Liu et al. 2008; Xing and Dai 2009; Yuan et al. 2010) . The biocompatibility, readily modifiable surface and optical properties originating from defects within their crystal lattice combine to make nanodiamonds extremely promising for use in biological environments. This review will focus on the characteristics, experimental progress and potential uses of a particular nanodiamond sub-class: luminescent nanodiamonds.
In the following sections we consider the key areas for successful implementation of luminescent nanodiamonds in biomedical applications, including material properties and fabrication strategies, surface modification and functional-isation and behaviour and effects in a biological environment. Experimental outcomes within each of these areas will ultimately determine the suitability of nanodiamonds as a practical luminescent bio-probe. Pragmatically, there needs to be a niche in which the use of nanodiamonds, instead of conventional luminescent bio-probes, such as quantum dots or polystyrene beads, is advantageous. We will explore some of the examples where nanodiamonds have been biologically applied and the most promising areas where nanodiamonds could make an impact.
Nitrogen-vacancy centres in nanodiamond
The diverse physical and chemical properties and proposed uses of nanodiamonds depend on how they are produced. There are three major approaches to diamond synthesis: high-pressure high-temperature (HPHT), chemical vapour deposition (CVD) and detonation synthesis (DND). Nanodiamonds can also be produced by milling down larger natural or synthetic crystals. The formation of natural diamonds occurs about 200 km below the earth's surface at pressures of 70-80 kbar and temperatures of 1400-1600°C (Balmer et al. 2009 ). HPHT synthesis reproduces these conditions in the laboratory using large presses capable of achieving similar high pressures and temperatures in a controlled environment (Bundy et al. 1955; Field 1992) . In CVD synthesis, hydrocarbon gas mixtures are ionised and, through a series of reactions, the carbon atoms are deposited onto a substrate to grow diamond films (Angus et al. 1993; Spear and Dismukes 1994; Butler and Sumant 2008; Balmer et al. 2009 ). DND forms in a process where carbon-containing explosives are detonated in the absence of oxygen. The explosion creates an instantaneously high temperature and pressure environment that results in the carbon being converted into diamond. The final product is always rich in graphite and other nondiamond carbon forms, which then require extensive mechanical and chemical processing to remove. The advantage of DND is the uniformly small size (4-5 nm) of the diamond grains, which is comparable to conventional fluorophores and suitable for biological applications (Danilenko 2004; Davydov et al. 2007) .
Luminescence in nanodiamonds produced from all of these different synthesis techniques is due to the incorporation of defects in the crystal lattice. More than 500 unique optical centres have been identified in diamond (Zaitsev 2001) , and several of these, including the nitrogen-vacancy (NV) (Davies and Hamer 1976; Gruber et al. 1997) , silicon-vacancy (SiV) (Tomljenovic-Hanic et al. 2009 ), nickel-related (Gaebel et al. 2004; Rabeau et al. 2005; Wu et al. 2006 ) and chromium centres (Aharonovich et al. 2010) , have been targeted for applications in both quantum technologies (Prawer and Greentree 2008) and biomedical imaging (Hui et al. 2010) . The NV centre is the most widely studied colour centre because of its stable photo-luminescence at room temperature and optically measurable and controllable spin states (Diep Lai et al. 2010) . The remainder of this review article will focus primarily on the NV centre; however, we will also briefly discuss broader applications of nanodiamonds in biomedicine.
NV centres are atomic impurities in the diamond lattice which include a substitutional nitrogen atom adjacent to a vacancy or 'hole' in the lattice (Fig. 1a ) (Davies and Hamer 1976) . This vacancy enables them to carry a negative or neutral charge . A number of processing techniques have been developed to artificially create the NV centre in diamond, including nitrogen implantation (Kalish et al. 1997 ) and electron (Dyer and Du Preez 1965) or ion (Chang et al. 2008b) irradiation. In the context of bioimaging, the most noteworthy feature, of the more abundant, negatively charged NV centre is that it can be optically excited between 480 and 580 nm to emit a broad luminescence band centred at 690 nm ( Fig. 1b) with an excited state lifetime of approximately 17 ns (Fu et al. 2007) .
Nanodiamonds possessing NV centres have several remarkable qualities that make them more attractive for use as probes in biomedical imaging than conventional fluorophores, such as organic fluorescent dyes and quantum dots (Table 1 ). The advantages of quantum dots as bioprobes are their relatively long luminescence signal and their emission wavelength, which is tuneable (Alivisatos 1996; Lidke and Arndt-Jovin 2004 ) . However, for the imaging of medium-to long-term biological processes, quantum dot luminescence is intermittent and eventually bleaches (Lee and Osborne 2007) . Moreover, quantum dots exhibit long-term cytotoxicity as their chemical components leach into the cytoplasm . In comparison, nanodiamonds with NV centres are photostable, have a low toxicity to cells and also display a quantum yield close to unity. The emission wavelength of NV-containing nanodiamonds (625-800 nm) can also penetrate into tissues and is well beyond the range of cellular autofluorescence (300-500 nm) (Billinton and Knight 2001) . Although a single quantum dot is threefold brighter than a nanodiamond containing a single NV centre, it is likely that with optimised fabrication, nanodiamonds will have fluorescence intensities comparable to or brighter than quantum dots (Faklaris et al. 2009a ). Together, these qualities make nanodiamonds ideal for imaging long-lived biological processes.
Surface functionalisation of nanodiamond
For biological applications, it is essential to modify the surface of nanodiamonds to enable conjugation to specific molecules. Nanodiamond surfaces are typically covered in a variety of oxygen-rich functional groups, including esters, hydroxyls and carboxylic acids (Schrand et al. 2009 ). The process for nanodiamond functionalisation usually begins with nitric and/or sulphuric acid treatment, which removes the surface graphite and uniformly terminates the diamond surface with hydrophilic oxygen-containing groups (Ando et al. 1993) . Alternatively, nanodiamonds can also be treated with reducing agents, leaving the nanodiamond surface hydrogen terminated and hydrophobic (Krüger et al. 2006; Börsch et al. 2009 ). Approaches used to obtain each of these terminations (Fig. 2) are shown in Table 2 .
After oxidation or reduction of the nanodiamond surface, biomolecules can either be covalently or non-covalently bound. Oxidised nanodiamonds typically non-covalently adsorb bio-active molecules via hydrogen bonding, electrostatic or other polar interactions (physisorption), while hydrogen-terminated nanodiamonds are less likely to adsorb biomolecules (Steinmüller-Nethl et al. 2006; Barnard and Sternberg 2007; Krueger 2008) . Although non-covalent bonding is often easier to achieve, the target moieties have a tendency to dissociate over time. In contrast, covalent bonding between the biomolecule and the nanodiamond is more stable and controllable, although it usually requires additional surface pre-activation to enable reactivity with the target molecule. A list of functional groups which have been produced on the surface of the nanodiamonds can be found in Table 3 . These preparative steps have enabled a variety of (Mohan et al. 2010b) 0.99 (Mohan et al. 2010b) 7.9 × 10 3 Photostable, only blinks when NV centre is close to surface (Bradac et al. 2010) Non-toxic below 400 μg/mL ( Luminescence spectrum of an NV -centre at room temperature excited by a 532-nm laser biologically active molecules to be non-covalently (Table 4) or covalently (Table 5 ) attached to nanodiamonds. For instance, poly-L-lysine has been both physisorbed (Huang and Chang 2004; Kong et al. 2005a; Huang et al. 2008 ) and covalently bonded via carbodiimide chemistry (Fu et al. 2007; Lim et al. 2009 ) onto the surface of acid-oxidised nanodiamonds. Other nanodiamonds have been reduced with borane, had silanes grafted to their surfaces and then were covalently bonded to biotin, a widely used universal receptor for streptavidin in biological labelling techniques (Neugart et al. 2007; . The wide variety of producible surface functional groups (Table 3) allows for a diverse range of bio-molecules to interact with the nanodiamond surface (Tables 4, 5 ).
Nanodiamond aggregation
Even after considerable surface treatments, as described above, nanodiamonds have a strong tendency to (re)aggregate in solutions and in cells, and this tendency increases with decreasing size of the nanodiamonds (Eidelman et al. 2005; Chao et al. 2007; Yuan et al. 2009 ). For biomedical imaging, nanodiamonds should remain separate from one another to facilitate maximal effective reaction and attachment to relevant molecules and to allow for internalisation into cells. Intracellular imaging also requires nanodiamonds of <10 nm in size. These conditions make uniform and stable de-aggregation essential. Methods currently used to de-aggregate nanodiamonds include acid treatments, Table 2 Approaches used to oxidize and reduce nanodiamond surfaces
Oxidation/carboxylation Reduction
Acid treatments: Hydrogen plasma treatment (Thoms et al. 1994; Strother et al. 2002; Knickerbocker et al. 2003 ) -Nitric and sulphuric acid (Kong et al. 2005a; Huang and Chang 2004; Liu et al. 2008; Chao et al. 2007; Ushizawa et al. 2002) Annealing in hydrogen gas (Härtl et al. 2004; Christiaens et al. 2006; Saini et al. 2008 ) -Nitric acid Huang et al. 2008; Sushchev et al. 2008; Mitev et al. 2007) Water vapour treatment (Ando et al. 1996a ) -Hydrochloric acid (Kossovsky et al. 1995; Mitev et al. 2007) Borane (BH3) (Krüger et al. 2006; Neugart et al. 2007; Liang et al. 2009; Zhang et al. 2009b) -Perchloric acid (Xu et al. 2005 ) -Potassium dichromate and sulphuric acid (Mitev et al. 2007 ) -Sulfuric acid and potassium permanganate (Xu et al. 2005) Annealing in:
Lithium Aluminum hydride (Hens et al. 2008; Zheng et al. 2009; -Ozone (Petrov et al. 2007; Krüger et al. 2006 ) -Air (Mochalin and Gogotsi 2009; Osswald et al. 2006; Shenderova et al. 2006; John et al. 2003; Mitev et al. 2007) ND ND Oxidation Reduction ND Fig. 2 A nanodiamond with a mixed composition of surface groups can be oxidised and terminated with oxygencontaining functional groups or reduced to produce a homogeneous hydrogen surface termination bead milling and sonication (Krüger et al. 2005; Fu et al. 2007; Faklaris et al. 2008) . Through a combination of these techniques we were first able to observe NV centres in isolated 5-nm nanodiamonds (Bradac et al. 2010 ). However, in order to achieve long-term stability, the repulsive forces between the particles must be increased. This can be done by atmospheric plasma treatment with nitrogen or hydrogen (Gibson et al. 2009 ), annealing in hydrogen gas (Williams et al. 2010) or treatment with NaCl or sodium oleate (Xu et al. 2005) . Functionalisation with some biomolecules, such as poly-L-lysine (Vaijayanthimala et al. 2009 ) and bovine serum albumin (Yuan et al. 2009 ), can also increase nanodiamond solubility and reduce re-aggregation. The Table 4 Various biological moieties which have been physisorbed to nanodiamonds
Proteins/Enzymes Toxins Other:
-apoobelin ) -aflatoxin B1 (AfB1) ) -DNA (Fu et al. 2007 ) -luciferase Puzyr' et al. 2004) -Alpha-bungarotoxin (Liu et al. 2008 (Miller and Brown 1996; Knickerbocker et al. 2003; Lu et al. 2004; Strother et al. 2002; Yang et al. 2002; Takahashi et al. 2003; Yeap et al. 2008; Zhang et al. 2009b; Zheng et al. 2009; Chang et al. 2010 ) (Strother et al. 2002; Takahashi et al. 2003; Ida et al. 2003; Tsubota et al. 2003; Härtl et al. 2004; Christiaens et al. 2006; Chang et al. 2010 ) (Liu et al. 2004; Ando et al. 1996b; Khabashesku et al. 2005; Ando et al. 1996a; Ando et al. 1993 ) (Ando et al. 1996a; Ikeda et al. 1998; Takahashi et al. 2003; Miller and Brown 1996) Silanes Aryl Alkyl Amino (Zhang et al. 2009b; Liang et al. 2009; Krüger et al. 2006; Yeap et al. 2008 Zheng et al. 2009) choice of biological buffer systems or media is also important, since both foetal bovine serum and phosphate buffered saline, two common biological buffer systems, tend to cause re-aggregation (Neugart et al. 2007; Vaijayanthimala et al. 2009 ). Despite the challenges involved in preparing and maintaining de-aggregated nanodiamonds, positive results strongly support their use in biological applications.
Bio-compatibility of nanodiamond
The stability and innate biocompatibility of carbon in nanodiamond significantly mitigates biochemical interactions within the host cell. The measurement of mitochondrial damage using the methyl thiazolyl tetrazolium assay revealed that the toxicity of nanodiamonds (Schrand et al. 2009 ) in a wide range of cell lines is extremely low (Table 6 ). In acute conditions, cells tolerate concentrations up to about 400 μg/mL of raw or surface functionalised nanodiamonds in vitro Chao et al. 2007; Liu et al. 2007; Schrand et al. 2007; Faklaris et al. 2008; Vaijayanthimala et al. 2009 ), with a decrease by approximately 20% in cell viability in some cancer cells at concentrations of 4 × 10 7 nanodiamonds/mL (Burleson et al. 2009 ). Protein expression ), rates of cellular proliferation and differentiation (Vaijayanthimala et al. 2009 ), as well as rates of apoptosis ) have all been used to show nanodiamond in vitro biocompatibility. This is further borne out by the low levels of reactive oxygen species measurable in treated cells since high levels of reactive oxygen species are a common sign of cell stress (Schrand et al. 2007 ). In chronic conditions, there has also been little or no discernable difference between treated lung cancer and embryonic fibroblast cells and control cells ). Thus, in contrast to other nanoparticle labels, such as quantum dots, which release biologically toxic substances over time , there is good evidence for the biocompatibility of nanodiamond-based labeling schemes in vitro. In contrast to in vitro labeling, in vivo tests have shown a higher degree of toxicity. Nanodiamond exposure has been tested by topical application to the skin and intratracheal administration. In one study, the application of nanodiamonds to the skin of mice did not cause contact hypersensitivity or other allergic reactions (Burleson et al. 2009 ). At a dose of 1mg/kg, Other -DNA (Christiaens et al. 2006; Takahashi et al. 2003; Knickerbocker et al. 2003; Lu et al. 2004; Rezek et al. 2006; Yang et al. 2002 ) -DNA (Ushizawa et al. 2002 ) (ester linkage) Table 6 Cells showing good biocompatibility with nanodiamond in vitro HeLa cells (human cervical carcinoma) (Faklaris et al. 2008; Vaijayanthimala et al. 2009 ) Human lung adenocarcinoma cells Liu et al. 2007; Liu et al. 2009 ) Keratinocytes (Burleson et al. 2009; Schrand et al. 2007 ) Neuroblastomas (Schrand et al. 2007 ) PC-12 cells (Schrand et al. 2007) Lung fibroblasts Embryonic fibroblasts Vaijayanthimala et al. 2009 ) Human kidney cells Osteoprogenitor cells (Vaijayanthimala et al. 2009 ) Macrophages (Schrand et al. 2007) 4 nm nanodiamonds instilled into the mouse trachea were phagocytosed by alveolar macrophages within 24 h, with a decrease in the number of nanodiamonds observed in the alveolar area throughout the study. Histopathological and ultrastructural investigations at 7, 14 and 28 days postexposure also showed no adverse effects in the lungs; nor did nanodiamonds evidently translocate into the bloodstream and/or other organs (Yuan et al. 2010) . However, in another study utilising significantly higher doses administered intratracheally (4 and 20 mg/kg), the mice showed some signs of toxicity over a shorter 3 day timeframe .
The bio-toxicity of nanodiamond via more invasive routes, such as injection beneath the skin (subcutaneously), injection into the lining of the abdominal cavity (intraperitoneally) and injection into the blood (intravenously), have also been studied. Subcutaneous and intraperitoneal (Mitura et al. 2001; Bakowicz and Mitura 2002) injections into mice and rats, respectively, showed that aggregates of nanodiamonds could be found adjacent to undamaged cells ) and that there was little local inflammatory response (Mitura et al. 2001; Bakowicz and Mitura 2002) . The mice also showed no signs of weight-loss or other clinical signs of toxicity even 28 days after the intravenous injection of nanodiamonds (Yuan et al. 2009 ). However, intravenous injection of nanodiamonds into rabbits showed a shortterm increase in serum bilirubin, suggesting an increase in red blood cell lysis, even though red blood cell numbers and haemoglobin concentration remained constant. A number of other changes were also observed, such as decreased serum cholesterol and low-density lipoproteins and increased triglycerides, suggesting metabolic changes, probably associated with the sequestering of the nanodiamonds in the liver .
Since the accumulation of intravenously injected nanodiamonds has important implications for applications such as drug delivery, their distribution within the body was studied with I 125 -conjugated nanodiamonds (Yuan et al. 2009 ). The nanodiamonds were found to be rapidly sequestered into the liver (approx. 40%) with the lungs (approx. 6%) and spleen (approx. 1%) exhibiting significantly lower uptake. Tests 28 days after injection showed that approximately 60% of the nanodiamonds were concentrated in the liver with less than 10% in the lungs (Yuan et al. 2009 ). These results suggest that the reticuloendothelial system plays a major role in the uptake (i.e. clearance) of nanodiamonds, as it does for other particulate matter in the blood. However, this uptake may well vary, depending on what is conjugated to the nanodiamonds. In terms of eventual loading, the importance of this pattern of uptake has functional implications for these organs as well as for individual cells.
Much research has focussed on the cellular interactions of nanodiamonds and their mechanisms of internalisation. Optical measurements based on luminescence Chao et al. 2007; Chang et al. 2008a, b; Faklaris et al. 2008 Faklaris et al. , 2009b Liu et al. 2009; Yuan et al. 2009; Zhang et al. 2009a) or Raman signatures ) have shown that nanodiamonds are internalised and tend to be located in endocytic vesicles, but they do not enter the nucleus. This has been confirmed by transmission electron microscopy and atomic force microscopy (Chang et al. 2008a, b; Faklaris et al. 2008 Faklaris et al. , 2009b Yu et al. 2005; Liu et al. 2009; Zhang et al. 2009a) .
Various pathways of cellular internalisation have been suggested (Nordsletten et al. 1996; Chang et al. 2008a; Liu et al. 2009 ). Studies with 25-30 nm nanodiamonds have shown that internalisation is predominantly receptormediated and clathrin-dependent (Faklaris et al. 2009b; Vaijayanthimala et al. 2009; Zhang et al. 2009a ). Thus, treating cells with sodium azide and 2-deoxyglucose, which reduces available energy for internalisation, or with phenyl arsine oxide, a clathrin-specific inhibitor, significantly reduces the internalisation of 140 nm nanodiamonds; in contrast, filipin, a caveolin-specific inhibitor does not. This result is further supported by clathrin staining during endocytosis ). However, nanodiamond size, conjugated functional groups, solution and cell type all influence the process. For example, Weng et al. (2009) found that transferrin-conjugated 100-nm diamonds were taken up via the abundant transferrin receptors on HeLa cells in a clathrin-dependant manner. In contrast, Cheng et al. (2007) observed that similar-sized nanodiamonds conjugated to growth hormone remained extracellular, presumably attached to the binding domain of the growth hormone receptor on A549 cells, while the unconjugated control nanodiamonds were internalised. Nanodiamonds can also be internalised by other receptormediated pathways. For instance, nanodiamonds conjugated to folate are internalised by caveolin-dependent endocytosis (Zhang et al. 2009a ). The possible internalisation pathways, distribution within the body and biocompatibility in vitro and in vivo make nanodiamonds promising bio-probes.
Nanodiamond applications: Imaging, tracking and molecular carriers
The biocompatibility of nanodiamonds has made it possible to use them in a multitude of possible applications in biomedicine. Their readily modifiable surface allows designated attachment of the widest possible variety of biologically interactive molecules, and their physical properties enable them to be detected by a wide range of modalities. As a consequence, a range of multimoded detection schemes are being recognised whereby the optical or spin signatures can be detected and tracked both in vivo and in vitro. In addition to a growing interest in the use of nanodiamonds to investigate and track physiological processes within cells, there is considerable interest in the use of nanodiamonds for targeted delivery of biological payloads to abrogate or modulate cell function.
Detection, imaging and tracking in vitro
The combination of images and signals produced by bright field and wide field epifluorescence has enabled the reconstruction of three-dimensional images and trajectories of nanodiamonds (Fig. 3) (Fu et al. 2007; Chang et al. 2008b; Zhang et al. 2009a ) more recently in real time (Faklaris et al. 2009a ) using single particle tracking within cells. As nanodiamonds do not enter the nucleus Chang et al. 2008a, b; Wee et al. 2009; Zhang et al. 2009a) and because their bright fluorescence is emitted beyond the range of cellular autofluorescence Fu et al. 2007; Fucikova et al. 2009; Weng et al. 2009 ), they can be used as cytoskeletal markers at concentrations as low as 1 μg/mL and detected using confocal fluorescence microscopy ). Furthermore, because of the long radiative lifetime of NV colour centres (approx. 17 ns) (Fu et al. 2007 ) relative to cell auto-fluorescence, time-gated confocal imaging can also be used to enhance the nanodiamond signal (Faklaris et al. 2008) . Two-photon excitation microscopy can further improve resolution and contrast and minimise background noise (Chang et al. 2008b) .
Alternatively, although giving much less architectural information, accurate quantitative studies have been performed using fluorescence-based cytometry. In these studies, nanodiamonds were internalised by or attached to cells via a specific molecule of interest. The quantitative information was then gathered from the emitted fluorescence of the cell population in a FACS-Array or from the individual cells in a flow cytometer (Liu et al. 2008; Li and Zhou 2010) . These approaches are important when the aim is to gather data from large numbers of cells, and they have been successfully used with fluorescent polystyrene beads for tracking macrophage lineage (i.e. using their phagocytic function) cells in vivo (Getts et al. 2008 ).
In vivo magnetic resonance imaging with nanodiamond-based contrast agents Magnetic resonance imaging (MRI) provides in vivo accessibility to physiological interactions of central importance in the detection and treatment of a wide range of diseases (Blamire 2008) . The use of nanodiamonds as MRI contrast agents has the potential to enable the monitoring of cellular events in intact tissue with a degree of specificity not provided by conventional MRI and is essential for the visualisation of particular cellular processes, such as receptor binding. Current targeted contrast agents go some of the way to meeting this challenge, with potential to track specific cells or receptors in vivo (Weissleder 1999) . However the sensitivity is inherently low and the contrast agents (Weissleder 1991) can be toxic.
One approach to achieving MRI contrast using nanodiamond is to attach a magnetic species, such as Gd(III) complexes, to the nanodiamond surface (Manus et al. 2010) . The presence of a paramagnetic metal shortens the longitudinal spin relaxation time (T1) of water protons in the surrounding tissue and leads to contrast in T1-weighted imaging (Caravan et al. 1999) . This technique has recently been demonstrated to enhance MRI contrast through covalent modification of the nanodiamond surface to allow the conjugation of Gd(III) complexes (Manus et al. 2010) .
A second approach is to directly detect the 13 C nuclear spins in the nanodiamond itself. The inherent difficulty with this technique is the low sensitivity of nuclear Reprinted by permission from Macmillan Publishers Ltd: Nature Nanotechnology (Chang et al. 2008b (Chang et al. ), copyright 2008 magnetism in combination with the low natural abundance of spin-active 13 C (1.1%) relative to 12 C. Methods to overcome this limitation include the production of nanodiamond grown from 13 C-rich sources and the use of nuclear hyperpolarisation (Hoch and Reynhardt 1988; Reynhardt and Terblanche 1997) which can dramatically increase the nuclear resonance signal.
Nanodiamonds as molecular carriers
The targeted delivery of therapeutic DNA (Zhang et al. 2009b) or cytotoxic drugs could maximise the efficacy of therapy as well as minimise the side effects and/or collateral damage to normal tissue in vivo. Nanodiamonds can potentially provide a delivery vehicle for these treatments. For example, doxorubicin (DOX) and paclitaxel (PTX), two cytotoxic drugs widely used in cancer chemotherapy, have been successfully and stably absorbed onto nanodiamonds Burleson et al. 2009; ). The more insoluble purvalanol A, and 4-hydroxytamoxifen, used more specifically in liver and breast cancer, respectively, have also been absorbed onto nanodiamonds while retaining their cytotoxicity ). Ironically, the undesirable tendency of nanodiamonds to form aggregates may provide a basis for more effective treatment in vivo, as the surface-adsorbed drug is initially released, followed by a more gradual and constant release of the drug from within the aggregates ). If successful, this strategy would reduce the need for systemic drug administration and produce a more sustained local exposure, potentially decreasing damage to remote healthy cells and reducing consequential clinical side-effects.
In itself, however, conjugating a drug to a nanodiamond does not produce targeted delivery. Recently, stable covalent conjugation of both I 125 -labelled bovine serum albumin and rabbit anti-mouse immunoglobulin G was reported with the antibody retaining its ability to bind to its cognate antigen (Purtov et al. 2010) . This result opens the door for specifically targeted delivery of a biological payload while simultaneously enabling tumour imaging in vivo via the local accumulation of luminescent nanodiamonds at the tumour site. As such, it represents a valuable means for optimising the efficacy of drugs and drug delivery. Such specific targeting would also enable the use of reduced amounts of highly toxic agents that would otherwise not achieve high enough local concentrations to be effective without catastrophic side-effects if given to patients systemically. This approach, while obvious for cancer, could easily be adapted for various infectious diseases, particularly infections by extracellular organisms, those with extracellular phases, such as malaria, and/or those expressing pathogen-specific molecules on infected cell surfaces. Furthermore, specific cellular subsets in diseases characterised by over-exuberant pro-inflammatory immune responses could be targeted and inactivated or destroyed, for example, in autoimmune disease and even certain infectious diseases (Getts et al. 2008; Getts et al. 2011) . Dually conjugated nanodiamonds could also be used to target cell subsets expressing a particular proinflammatory chemokine or cytokine receptor using the relevant chemokine or cytokine to deliver a behaviourmodifying signal to these cells . Such signals could be used to block migration or inhibit the proinflammatory response of the targeted cells.
Conclusions
The biomedical application of nanodiamonds in experimentation, diagnostics, drug delivery and therapeutics relies on the size, inertness, stability, fluorescence and a host of manipulable surface characteristics. The recent interest in this field has been driven by the promising results thus far obtained, which have further amplified interest in nanodiamonds. While still in its infancy, the use of nanodiamond holds enormous promise for biomedical diagnostics and therapeutics for both humans and animals.
